Insights
09 September 2024
OneVentures
Australian Investment Council announces 2024 investing for growth award winners
Read the full article: Australian Investment Council
investmentcouncil.com.au/site/AIC/Articles/Media-Release/2024/AIC-announces-2024-Investing-for-Growth-Awards.aspx#:~:text=Pacific%20Equity%20Partners%20and%20OneVentures,the%20private%20capital%20investment%20community.
investmentcouncil.com.au/site/AIC/Articles/Media-Release/2024/AIC-announces-2024-Investing-for-Growth-Awards.aspx#:~:text=Pacific%20Equity%20Partners%20and%20OneVentures,the%20private%20capital%20investment%20community.
29 August 2024
Growth Equity
OneVentures raising $200m to fill gap left by corporate venture capital funds
Read the full article: The Australian
theaustralian.com.au/subscribe/news/1/?sourceCode=TAWEB_WRE170_a&dest=https%3A%2F%2Fwww.theaustralian.com.au%2Fbusiness%2Ftechnology%2Foneventures-raising-200m-to-fill-gap-left-by-corporate-venture-capital-funds%2Fnews-story%2Fbd0bb5a86e50e6d662490d434a4c442d&memtype=anonymous&mode=premium&v21=GROUPB-Segment-2-NOSCORE&V21spcbehaviour=append
theaustralian.com.au/subscribe/news/1/?sourceCode=TAWEB_WRE170_a&dest=https%3A%2F%2Fwww.theaustralian.com.au%2Fbusiness%2Ftechnology%2Foneventures-raising-200m-to-fill-gap-left-by-corporate-venture-capital-funds%2Fnews-story%2Fbd0bb5a86e50e6d662490d434a4c442d&memtype=anonymous&mode=premium&v21=GROUPB-Segment-2-NOSCORE&V21spcbehaviour=append
29 November 2023
Healthcare
US FDA Grants the BiVACOR Total Artificial Heart IDE Approval for First-in-Human Early Feasibility Study
Read the full article: Business Wire
businesswire.com/news/home/20231129194008/en/US-FDA-Grants-the-BiVACOR-Total-Artificial-Heart-IDE-Approval-for-First-in-Human-Early-Feasibility-Study
businesswire.com/news/home/20231129194008/en/US-FDA-Grants-the-BiVACOR-Total-Artificial-Heart-IDE-Approval-for-First-in-Human-Early-Feasibility-Study
18 June 2023
Healthcare
Vaxxas opens world-class manufacturing facility to produce needle-free vaccine patch
Read the full article: Vaxxas
businesswire.com/news/home/20230618635444/en/Vaxxas-Opens-World-Class-Manufacturing-Facility-To-Produce-Proprietary-Needle-Free-Vaccine-Patch-For-Late-Stage-Clinical-Trials-and-First-Commercial-Products
businesswire.com/news/home/20230618635444/en/Vaxxas-Opens-World-Class-Manufacturing-Facility-To-Produce-Proprietary-Needle-Free-Vaccine-Patch-For-Late-Stage-Clinical-Trials-and-First-Commercial-Products
